At the first clinical signs of CHF,
VETMEDIN is a versatile, first-line therapy for canine congestive heart failure (CHF). VETMEDIN has been shown to extend survival compared with treatment with angiotensin-converting enzyme (ACE) inhibitors alone1,2 and to improve quality of life.1
When used from the start of clinical signs as part of a standard CHF treatment protocol, VETMEDIN keeps dogs going.
VETMEDIN is indicated for the management of the signs of mild, moderate, or severe CHF in dogs due to atrioventricular valvular insufficiency (AVVI) or dilated cardiomyopathy (DCM).3,4
VETMEDIN is also approved for concurrent use with other cardiac treatments (eg, furosemide) as appropriate on a case-by-case basis.3,4
Recommended by the ACVIM
VETMEDIN is recommended by the American College of Veterinary Internal Medicine (ACVIM) for use as standard first-line therapy at the onset of clinical signs of CHF.5 Read more
1. Lombard CW, Jöns O, Bussadori CM; for the VetSCOPE Study. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006;42(4):249–261.
2. Häggström J, Boswood A, O’Grady M, et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med. 2008;22(5):1124–1135.
3. VETMEDIN® (pimobendan) Chewable Tablets [Freedom of Information
Summary]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2007.
4. VETMEDIN® (pimobendan) Chewable Tablets [package insert]. St. Joseph,
MO: Boehringer Ingelheim Vetmedica, Inc.; 2007.
5. Atkins C, Bonagura J, Ettinger S, et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009;23(6):1142–1150.